Ocuphire Pharma Results

Preclinical Data: Oral APX3330 Blocks Neovascularization Lesion Volume Decrease with Oral APX3330 in Murine Laser CNV Model Similar to EYLEAⓇ Data L-CNV Mouse Retina Model Lesion Size and Corresponding Fluorescent Stains in L-CNV Models Treated with APX3330 at 25 mg/kg oral gavage Silva et al, 2021 Vehicle Ocuphire PHARMA APX3330 25 mg/kg 50 mg/kg Lesion Volume (µm³) APX3330 Gavage OCT Lesion Volume 8x106 6x106 4x106- 2x106- 0 **** *** -55%. Vehicle 25 50 [APX3330] (mg/kg) (a) Silva et al. ARVO 2021 Annual Meeting *Published data on EYLEA. This study was performed independently from APX3330 study and is a cross-study comparison. **Li 2014; *** Pasha 2018; **** *Jiang 2011 (Vldlr -/- Very Low-Density Lipoprotein receptor knock-out mice) Day 7 (c) Day 14 ONL RPE L-CNV Mouse Retina Model Vehicle *EYLEA Anti-VEGF164 CNV lesion volume (um³) 1.2x107- 9.0x106- -44% ✓ Efficacy was also seen after single intravitreal injection of 20 µM APX3330 in mouse L-CNV model** ✓ Efficacy was also seen after dosing intraperitoneal injection of 50 mg/kg twice daily, 5 days on/2 days off, for 2 weeks in mouse L-CNV model** *** ✓ Efficacy was also seen after single intravitreal injection of 20 µM APX3330 in Vldlr / mice model* 6.0x106- 3.0x106- 0.0 Vehicle Anti-VEGF164 36

View entire presentation